Amit R. Nayak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amit R. Nayak has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aliabbas A. Husain
Advanced Research Center, Central India Institute of Medical Sciences, Bajaj Nagar, Nagpur, Maharashtra, India
4 shared publications - Rajpal Singh Kashyap
Research Centre, Central India Institute of Medical Sciences, Nagpur, India
4 shared publications - Hatim F. Daginawala
Biochemistry Research Laboratory, Central India Institute of Medical Sciences, Nagpur, India
3 shared publications - Akshata Nandanwar
Advanced Research Center, Central India Institute of Medical Sciences, Bajaj Nagar, Nagpur, Maharashtra, India
2 shared publications - Dewanand R. Kalorey
Department of Veterinary Microbiology and Animal Biotechnology, Nagpur Veterinary College, Nagpur, India
2 shared publications Dinesh P. Kabra
Biochemistry Research Laboratory, Central India Institute of Medical Sciences
2 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by Maharshi Charaka Ayurveda Organization in Journal of Ayurveda and Integrated Medical Sciences
- Vol. 11 (8) , 207-217
Perspectives of in silico studies on Cow Urine Distillate as a Bioenhancer in Infectious and Non-infectious disease therapeutics: A Review
The global rise in anti-microbial resistance with the limited bioavailability and suboptimal pharmacokinetic performance of conventional therapeutics, it has intensified the interest in natural bioenhancer capable of improving therapeutics, having intensified the interest in natural bioenhancer thus capable of improving therapeutic efficacy across infectious and non-infectious disease settings. Cow urine distillate (CUD), an Ayurvedic preparation, has showcased the immunomodulatory, anti-inflammatory, antimicrobial, and bioavailability-enhancing properties. The in-silico investigation explored CUD-derived bioactive constituents as a multi-target bioenhancer, having its key role on vivid and diverse molecular pathways that act in fungal, parasitic, bacterial, viral, inflammatory, and immune-mediated disorders. Computational studies have revealed the CUD phytochemicals and key pathogen targets, like penicillin-binding protein 2a (PBP2a), topoisomerase IV, viral proteases, β-tubulin, and glutathione S-transferase, RNA-dependent RNA polymerase, lanosterol 14-α-demethylase (CYP51), host-regulatory targets such as cyclooxygenase-2 (COX-2), nuclear factor-κB (NF-κB), and Toll-like receptors. Literature suggests that primary constituents, including cinnamic acid, ferulic acid, indole, and hexanoic acid, are evaluated by in silico tools like AutoDock Vina, MOE, and Schrödinger Glide, Molecular Dynamics (MD) simulations to assess binding stability and conformational behavior. Molecular Docking results are indicative of stable binding affinities and in silico ADMET analyses by using SwissADME and pkCSM, predicting favorable oral bioavailability and low toxicity profiles compatible with adjunctive use. Network pharmacology analyses support a polypharmacological mode of action targeting both pathogen survival pathways and host immune-inflammatory signaling. The available in silico evidence proves CUD as a promising multi-target bioenhancer; systematic in vitro and in vivo validation are essential to substantiate its translational potential.
- 20 September 2026
- Published by Maharshi Charaka Ayurveda Organization in Journal of Ayurveda and Integrated Medical Sciences
- Vol. 11 (8) , 207-217
Open AccessPerspectives of in silico studies on Cow Urine Distillate as a Bioenhancer in Infectious and Non-infectious disease therapeutics: A Review
The global rise in anti-microbial resistance with the limited bioavailability and suboptimal pharmacokinetic performance of conventional therapeutics, it has intensified the interest in natural bioenhancer capable of improving therapeutics, having intensified the interest in natural bioenhancer thus capable of improving therapeutic efficacy across infectious and non-infectious disease settings. Cow urine distillate (CUD), an Ayurvedic preparation, has showcased the immunomodulatory, anti-inflammatory, antimicrobial, and bioavailability-enhancing properties. The in-silico investigation explored CUD-derived bioactive constituents as a multi-target bioenhancer, having its key role on vivid and diverse molecular pathways that act in fungal, parasitic, bacterial, viral, inflammatory, and immune-mediated disorders. Computational studies have revealed the CUD phytochemicals and key pathogen targets, like penicillin-binding protein 2a (PBP2a), topoisomerase IV, viral proteases, β-tubulin, and glutathione S-transferase, RNA-dependent RNA polymerase, lanosterol 14-α-demethylase (CYP51), host-regulatory targets such as cyclooxygenase-2 (COX-2), nuclear factor-κB (NF-κB), and Toll-like receptors. Literature suggests that primary constituents, including cinnamic acid, ferulic acid, indole, and hexanoic acid, are evaluated by in silico tools like AutoDock Vina, MOE, and Schrödinger Glide, Molecular Dynamics (MD) simulations to assess binding stability and conformational behavior. Molecular Docking results are indicative of stable binding affinities and in silico ADMET analyses by using SwissADME and pkCSM, predicting favorable oral bioavailability and low toxicity profiles compatible with adjunctive use. Network pharmacology analyses support a polypharmacological mode of action targeting both pathogen survival pathways and host immune-inflammatory signaling. The available in silico evidence proves CUD as a promising multi-target bioenhancer; systematic in vitro and in vivo validation are essential to substantiate its translational potential.
- Open Access
- 12 August 2026
- Published by Maharshi Charaka Ayurveda Organization in Journal of Ayurveda and Integrated Medical Sciences
- Vol. 11 (7) , 292-303
Computational Insights on Cow urine distillate used as a Bioenhancer in Cancer Therapy
Cancer poses a significant global health burden, aligning conventional therapies limited by poor drug bioavailability, systemic toxicity, and the development of chemoresistance. The aligning challenges have showcased the growing interest in natural bioenhancers, which are capable of improving therapeutic efficacy while mitigating adverse effects. Cow urine distillate (CUD), a traditional Ayurvedic preparation that is derived from Bos indicus, holds impressive research data in terms of immunomodulatory, antioxidant, and bioavailability-enhancing properties. CUD constitutes phytochemicals like ferulic acid, cinnamic acid, and phenylethanol, and cinnamic acid shows favorable binding affinities in docking studies performed with in silico tools like AutoDock Vina, Schrödinger Glide, and Molecular Operating Environment. As the research literature indicates, molecular dynamics simulations show a stable ligand receptor with reported minimal conformational fluctuation. The in silico investigations has revealed the potential of CUD derived phytochemicals as adjuvants in oncology with the primary cancer associated molecular targets including Cyclin dependent kinases, DNA topoisomerase II, epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), vascular endothelial growth factor receptor (VEGFR), protein kinase B (Akt), Bcl-2, and matrix metalloproteinases are widely researched and explored using high-resolution structures from the Protein Data Bank. In silico ADMET profiling ensured by SwissADME and pkCSM gives good oral absorption, drug-likeness, and low predicted toxicity, supporting translational feasibility. Network pharmacology analyses have reported multi-target modulation of pathways controlling apoptosis, proliferation, angiogenesis, inflammation, immune response, and therapeutic resistance. Computational insights give the rationale for the mechanism for CUD as a multitarget natural bioenhancer. Showing the need for systematic in vitro, in vivo, and clinical studies to validate its bioenhancing and adjunctive potential in cancer therapeutics.
- 12 August 2026
- Published by Maharshi Charaka Ayurveda Organization in Journal of Ayurveda and Integrated Medical Sciences
- Vol. 11 (7) , 292-303
Open AccessComputational Insights on Cow urine distillate used as a Bioenhancer in Cancer Therapy
Cancer poses a significant global health burden, aligning conventional therapies limited by poor drug bioavailability, systemic toxicity, and the development of chemoresistance. The aligning challenges have showcased the growing interest in natural bioenhancers, which are capable of improving therapeutic efficacy while mitigating adverse effects. Cow urine distillate (CUD), a traditional Ayurvedic preparation that is derived from Bos indicus, holds impressive research data in terms of immunomodulatory, antioxidant, and bioavailability-enhancing properties. CUD constitutes phytochemicals like ferulic acid, cinnamic acid, and phenylethanol, and cinnamic acid shows favorable binding affinities in docking studies performed with in silico tools like AutoDock Vina, Schrödinger Glide, and Molecular Operating Environment. As the research literature indicates, molecular dynamics simulations show a stable ligand receptor with reported minimal conformational fluctuation. The in silico investigations has revealed the potential of CUD derived phytochemicals as adjuvants in oncology with the primary cancer associated molecular targets including Cyclin dependent kinases, DNA topoisomerase II, epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), vascular endothelial growth factor receptor (VEGFR), protein kinase B (Akt), Bcl-2, and matrix metalloproteinases are widely researched and explored using high-resolution structures from the Protein Data Bank. In silico ADMET profiling ensured by SwissADME and pkCSM gives good oral absorption, drug-likeness, and low predicted toxicity, supporting translational feasibility. Network pharmacology analyses have reported multi-target modulation of pathways controlling apoptosis, proliferation, angiogenesis, inflammation, immune response, and therapeutic resistance. Computational insights give the rationale for the mechanism for CUD as a multitarget natural bioenhancer. Showing the need for systematic in vitro, in vivo, and clinical studies to validate its bioenhancing and adjunctive potential in cancer therapeutics.
- Open Access
- 24 January 2025
- Published by Springer Nature in Research Square
Establishing a Middle Cerebral Artery Occlusion (MCAO) Model with Simplified Surgical Tools: A Resource-Efficient Strategy for Stroke Research
This study aimed to develop a cost-effective middle cerebral artery occlusion (MCAO) model in rats using an intraluminal suture method with a magnifying glass lens, an alternative to a surgical microscope. Male Sprague-Dawley rats underwent MCAO surgery, and neurological deficits were assessed post-surgery. Neurological scores were significantly higher in MCAO rats (mean score 3.5 ± 0.5) compared to sham-operated controls (mean score 0.5 ± 0.2) (p < 0.001). 2,3,5-Triphenyltetrazolium chloride (TTC) staining revealed significant infarction in the ischemic region (mean infarct volume 45.2 ± 5.6%), while no infarct was observed in sham-operated controls (0%). Histopathological analysis confirmed ischemic damage, and immunofluorescence staining showed reduced NeuN (62.4% ± 8.2%) and GFAP (70.3% ± 7.5%) expression in the ischemic cortex compared to sham (p < 0.01). Brain water content was significantly higher in the ischemic hemisphere (82.5% ± 2.1%) compared to the contralateral hemisphere (78.4% ± 1.3%) (p < 0.05). The magnifying glass lens-based technique provided a reliable, cost-effective alternative for MCAO surgery, maintaining high reproducibility. This model can be used for preclinical stroke research, neuroprotective studies, and investigating ischemic pathophysiology, especially in resource-limited settings. Overall, the magnifying glass lens MCAO model proves to be an effective tool for stroke research and translational studies in low-resource environments.
- 24 January 2025
- Published by Springer Nature in Research Square
Open AccessEstablishing a Middle Cerebral Artery Occlusion (MCAO) Model with Simplified Surgical Tools: A Resource-Efficient Strategy for Stroke Research
This study aimed to develop a cost-effective middle cerebral artery occlusion (MCAO) model in rats using an intraluminal suture method with a magnifying glass lens, an alternative to a surgical microscope. Male Sprague-Dawley rats underwent MCAO surgery, and neurological deficits were assessed post-surgery. Neurological scores were significantly higher in MCAO rats (mean score 3.5 ± 0.5) compared to sham-operated controls (mean score 0.5 ± 0.2) (p < 0.001). 2,3,5-Triphenyltetrazolium chloride (TTC) staining revealed significant infarction in the ischemic region (mean infarct volume 45.2 ± 5.6%), while no infarct was observed in sham-operated controls (0%). Histopathological analysis confirmed ischemic damage, and immunofluorescence staining showed reduced NeuN (62.4% ± 8.2%) and GFAP (70.3% ± 7.5%) expression in the ischemic cortex compared to sham (p < 0.01). Brain water content was significantly higher in the ischemic hemisphere (82.5% ± 2.1%) compared to the contralateral hemisphere (78.4% ± 1.3%) (p < 0.05). The magnifying glass lens-based technique provided a reliable, cost-effective alternative for MCAO surgery, maintaining high reproducibility. This model can be used for preclinical stroke research, neuroprotective studies, and investigating ischemic pathophysiology, especially in resource-limited settings. Overall, the magnifying glass lens MCAO model proves to be an effective tool for stroke research and translational studies in low-resource environments.
- Open Access
Prognostic value of serum MMP-9 level in acute ischemic stroke patient
Purpose: MMP-9 is reported to be a marker of severity and worse outcome after stroke. Despite the above information, there are very few studies based on the evaluation of role of follow-up estimation of serum MMP-9 in acute ischemic stroke (AIS) patients. The purpose of this study was to evaluate the role of follow-up estimation of serum MMP-9 in the prognosis of AIS patients. MMP-9 levels were also compared with reported biomarkers viz. Neuron-Specific Enolase (NSE), Glial specific protein (S100ββ) and Inter-α-trypsin inhibitor heavy chain 4 (ITIH4). Materials/methods: MMP-9, NSE, and S-100ββ were measured in serum samples collected at admission and expired/discharge time of AIS patients (n=48) using commercially available ELISA kits. ITIH4 was measured using Indirect ELISA protocol. Results: MMP-9 at admission (3639 ±1471) and discharged/expired (3707 ±1268) was significantly higher (p<0.05) in AIS patients as compared to healthy control subjects (749 ±302). Expired patients showed significantly (p<0.05) higher MMP-9 as compared to survivors. Similarly, follow-up MMP-9 at discharge was higher in AIS patients who expired within one year (75%; 3/4). The observed values of MMP-9 significantly correlates (p<0.05) with NSE (r=0.452), S-100ββ (r=0.452) and ITIH4 (r=-0.2027). Conclusions: Follow-up measurement of serum MMP-9 may help to predict both short term and long term mortality in AIS patients.
Open AccessPrognostic value of serum MMP-9 level in acute ischemic stroke patient
Purpose: MMP-9 is reported to be a marker of severity and worse outcome after stroke. Despite the above information, there are very few studies based on the evaluation of role of follow-up estimation of serum MMP-9 in acute ischemic stroke (AIS) patients. The purpose of this study was to evaluate the role of follow-up estimation of serum MMP-9 in the prognosis of AIS patients. MMP-9 levels were also compared with reported biomarkers viz. Neuron-Specific Enolase (NSE), Glial specific protein (S100ββ) and Inter-α-trypsin inhibitor heavy chain 4 (ITIH4). Materials/methods: MMP-9, NSE, and S-100ββ were measured in serum samples collected at admission and expired/discharge time of AIS patients (n=48) using commercially available ELISA kits. ITIH4 was measured using Indirect ELISA protocol. Results: MMP-9 at admission (3639 ±1471) and discharged/expired (3707 ±1268) was significantly higher (p<0.05) in AIS patients as compared to healthy control subjects (749 ±302). Expired patients showed significantly (p<0.05) higher MMP-9 as compared to survivors. Similarly, follow-up MMP-9 at discharge was higher in AIS patients who expired within one year (75%; 3/4). The observed values of MMP-9 significantly correlates (p<0.05) with NSE (r=0.452), S-100ββ (r=0.452) and ITIH4 (r=-0.2027). Conclusions: Follow-up measurement of serum MMP-9 may help to predict both short term and long term mortality in AIS patients.
- Open Access
- 4 October 2016
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 23 (4) , 199-208
Prediction of Outcome in Diabetic Acute Ischemic Stroke Patients: A Hospital-Based Pilot Study Report
Background: Demographic and clinical characteristics are known to influence the outcome in acute ischemic stroke (AIS) patients. Purpose: This study is aimed at evaluating short- and long-term outcomes in diabetic AIS patients. In addition, the study also evaluates the impact of diabetes on the performance of indigenously reported biomarker, inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) and known biomarkers, neuron-specific enolase (NSE) and glial-derived S-100 beta beta protein (S-100ββ). Methods: This study was performed on 29 diabetes and 75 non-diabetes AIS patients. Outcome of AIS patients was analyzed by using modified Rankin scale at discharge, then at 12 and 18 months after discharge. Based on the obtained scores, patients were classified as improved group (scales 1-3) and dependent/expired group (scales 3-6). Blood samples were collected during admission and at discharge/expired time. Levels of NSE, S100ββ, and ITIH4 were analyzed in all samples. Results: On discharge, frequencies of dependent/expired outcome were 4/29 (14%) and 19/75 (17%) in diabetic and non-diabetic AIS patients. However, follow-up outcome at 12 and 18 months showed higher dependent/expired cases of 43 and 41% among diabetic AIS patients compared to 27 and 21% in non-diabetic patients. Multivariate analysis revealed that diabetes is an independent risk factor for dependent/expired outcome in AIS patients (OR 0.484 (at discharge); 1.307 (at 12 months) and 1.675 (at 18 months)). NSE, S100ββ, and ITIH4 showed a differential expression in both the outcome groups of AIS patients, irrespective of diabetes. Conclusion: Diabetes increases the risk of dependent/expired outcome in AIS patients. Also, serum NSE, S100ββ, and ITIH4 are independent biomarkers for prognosis of outcome in AIS patients, irrespective of diabetes.
- 4 October 2016
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 23 (4) , 199-208
Open AccessPrediction of Outcome in Diabetic Acute Ischemic Stroke Patients: A Hospital-Based Pilot Study Report
Background: Demographic and clinical characteristics are known to influence the outcome in acute ischemic stroke (AIS) patients. Purpose: This study is aimed at evaluating short- and long-term outcomes in diabetic AIS patients. In addition, the study also evaluates the impact of diabetes on the performance of indigenously reported biomarker, inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) and known biomarkers, neuron-specific enolase (NSE) and glial-derived S-100 beta beta protein (S-100ββ). Methods: This study was performed on 29 diabetes and 75 non-diabetes AIS patients. Outcome of AIS patients was analyzed by using modified Rankin scale at discharge, then at 12 and 18 months after discharge. Based on the obtained scores, patients were classified as improved group (scales 1-3) and dependent/expired group (scales 3-6). Blood samples were collected during admission and at discharge/expired time. Levels of NSE, S100ββ, and ITIH4 were analyzed in all samples. Results: On discharge, frequencies of dependent/expired outcome were 4/29 (14%) and 19/75 (17%) in diabetic and non-diabetic AIS patients. However, follow-up outcome at 12 and 18 months showed higher dependent/expired cases of 43 and 41% among diabetic AIS patients compared to 27 and 21% in non-diabetic patients. Multivariate analysis revealed that diabetes is an independent risk factor for dependent/expired outcome in AIS patients (OR 0.484 (at discharge); 1.307 (at 12 months) and 1.675 (at 18 months)). NSE, S100ββ, and ITIH4 showed a differential expression in both the outcome groups of AIS patients, irrespective of diabetes. Conclusion: Diabetes increases the risk of dependent/expired outcome in AIS patients. Also, serum NSE, S100ββ, and ITIH4 are independent biomarkers for prognosis of outcome in AIS patients, irrespective of diabetes.
- Open Access
- 16 September 2015
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 22 (1) , 143-153
Heterologous Prime Boost Regimes with N-terminal Peptides of Ag85B Induces Better Protection than Ag85B and BCG in Murine Model of Tuberculosis
- 16 September 2015
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 22 (1) , 143-153
Open AccessHeterologous Prime Boost Regimes with N-terminal Peptides of Ag85B Induces Better Protection than Ag85B and BCG in Murine Model of Tuberculosis